INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces its financial and investor relations calendar for 2010 and the settlement and delivery of its capital increase

Transparency directive : regulatory news

23/12/2009 19:23

PRESS RELEASE

INNATE PHARMA ANNOUNCES ITS FINANCIAL AND INVESTOR RELATIONS CALENDAR FOR
2010 AND THE SETTLEMENT AND DELIVERY OF ITS CAPITAL INCREASE

Marseilles, France, December 23, 2009

Innate Pharma (the "Company" - Euronext Paris: FR0010331421 - IPH) announces
today its tentative financial and investor relations calendar for 2010. The
tentative financial calendar was set as follows:

February 5, 2010:  Publication of revenue for 4Q2009 and for fiscal year 2009,
                   with management comments.

March 5, 2010:    Publication of 2009 financial statements, with management
                   comments. The 2009 Reference Document and Financial Report
                   (included in the Reference Document) will be released during
                   the second quarter of 2010.

May 5, 2010:    Publication of revenue for 1Q2010, with management comments.

June 25, 2010:    Annual shareholders meeting, in Marseilles.

August 31, 2010:   Publication of mid-year financial statements as of June 30,
                   2010, with management comments.

November 5, 2010:  Publication of revenue for 3Q2010, with management comments.

February 4, 2011:  Publication of revenue for 4Q2010 and for fiscal year 2010,
                   with management comments.

All corporate information on the company such as its financial statements or its
corporate presentations is available on the company's website, in the investor
documentation centre, Investors' section (www.innate-pharma.com/investors-room).

The Company also announces today the settlement and delivery of its capital
increase reserved to categories of investors announced on December 18, 2009.
10,724,535 new shares were issued. The gross proceeds amount to 24.3 million
euros (issuance premium included) and the net proceeds amount to 23.1 million
euros.

Following the transaction, Novo Nordisk A/S, the Fonds stratégique
d'investissement (FSI) and Alta Partners are the main shareholders of the
Company with respectively 15.21%, 13.23% and 7.41% of the share capital and
voting rights of the Company.
The appointment of a representative of the FSI to the Supervisory Board of the
Company will be proposed at the next Shareholder's Meeting.

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biopharmaceutical company developing
first-in-class immunotherapy drugs for cancer and other severe diseases. The
Company was incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006.
The Company has two drug candidates currently in Phase II clinical trials. Two
of its preclinical programs are out-licensed to Novo Nordisk A/S.

Innate Pharma is based in Marseilles, France, and had 84 employees as at
September 30, 2009.

Learn more about Innate-Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code      FR0010331421
Ticker code    IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference (as updated)
filed with the AMF, which is available on the AMF website (www.amf-france.org)
or on Innate Pharma's website (www.innate-pharma.com).

A prospectus filed with the AMF on December 22, 2009 under n° 09-372, composed
of the Document de Reference of the Company filed on May 5, 2009 under n°
09-043, of its actualization filed on December 22, 2009 under n° 09-043-A01 and
of a note d'opération (that includes a summary of the prospectus) is available
free of charge from the Company and on the AMF website (www.amf-france.org) or
on Innate Pharma's website (www.innate-pharma.com). This prospectus has been
prepared solely in connection with the listing of the newly issued shares.

This press release does not constitute an offer or solicitation of an offer to
purchase or subscribe for securities to the public in France. The new shares may
not and will not be offered to the public in France.

This press release does not constitute an offer to sell, or a solicitation of
offers to purchase or subscribe for, securities in the United States. The
securities referred to herein have not been, and will not be, registered under
the U.S. Securities Act of 1933, as amended, and may not be offered or sold in
the United States absent registration or an applicable exemption from
registration requirements. Innate Pharma does not intend to register any portion
of offering of the securities in the United States. Copies of this announcement
are not being made and may not be distributed or sent into the United States,
Canada, Australia or Japan.

For additional information, please contact:

Innate Pharma                        Alize Public Relations
Laure-Hélène Mercier                   Caroline Carmagnol
Director, Investor Relations           Phone: +33 (0)1 41 22 07 31
Phone: +33 (0)4 30 30 30 87        Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.com        caroline@alizerp.com

091223_Financial calendar and capital increase delivery settlement

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces its financial and investor relations calendar for 2010 and the settlement and delivery of its capital increase

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories